All News

RA.vascular.cholesterol.plaque.jpg

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

d Jack Cush, MD

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Read Article
stress.sad_.bad%20news%20%5Bphotoutils.com%5D%20%281%29.jpg

Stress and the Risk of Incident Inflammatory Arthritis

d Jack Cush, MD

A prospective analysis of newly diagnosed, inflammatory arthritis (IA) patients suggests that perceived distress (stress) increases the odds of incident IA.

Read Article
eye.exam_.equip_.jpg

Hydroxychloroquine Blood Levels May Predict Future Retinopathy

d Jack Cush, MD

A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.

Read Article
Convention2.jpg

ACR 2018 - Day 1 Report

d RheumNow,  , EyeMah , , DenMah

Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.

Read Article
heart-attack.jpg

Juvenile Arthritis at Risk for Coronary Artery Disease

d Jack Cush, MD

Arthritis Care & Research reports that juvenile arthritis (JA) patients may have a higher risk if coronary artery disease (CAD) in adulthood. 

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – When You’re Hot You’re Hot (10.11.19)

d Jack Cush, MD

Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.

Read Article
nurse.referral.jpg

Long Delays for Inflammatory Arthritis Patients

d Jack Cush, MD

The National Rheumatoid Arthritis Society's (NRAS) annual audit has identified significant treatment delays for patients with suspected early inflammatory arthritis could result in unnecessary harm. 

Read Article
oaknees.jpg

Sprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis

d Jack Cush, MD

Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical benefits. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?

Read Article
RheumNow Survey for Rheumatologists – In Giant Cell Arteritis - When do you add a steroid sparing agent? https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

RISE registry: among 7,274 RA pts w/ serial data [RAPID3 (78.9%) & CDAI (34.2%)]. Amongst those w/ moderate/high disease activity, frequency of DMARD change was low (36%-55%). Less likely to change was elderly, Combo DMARDs or biologics. https://t.co/IppHCxJWk1

Links:

Dr. John Cush RheumNow ( View Tweet)

Followup of 783 tofacitinib‐treated psoriatic arthritis patients finds increases in LDL and HDL 9% to 14% after 3 and 6 months of therapy with a low risk of HTN or MACE events https://t.co/fh6UbmF3lr

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow LIVE VOTE Survey: When treating a patient for GCA, when might you add a steroid-sparing agent?? If youre a RHEUMATOLOGIST - please vote in our quick 4Q survey https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparison of 69 SLE pts w/ C/S+ infection vs 69 SLE without infx shows that serum procalitonin did not distinguish those w/ infection, BUT C-reactive protein did successfully identify those SLE patients with infection https://t.co/HMHqfaP0Cg

Links:

Dr. John Cush RheumNow ( View Tweet)

Taiwanese Claims data study shows the risk of opportunistic infection in ~77K autoimmune pts shows OI highes in PM/DM cases (61.3/1000PY), followed by SLE (43.1/1000PY), SSc (31.6), RA (25), and pSS (24.1). OI risk highest during 1st year https://t.co/YKP7ZF7FIx

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 179 RA pts achieving remission on TCZ- SC 162 mg qwk randomized to continue qWk or space out to q2Wk -- Weekly Actemra better maintained remission (90% versus 73%; P = 0.004), but then again 73% did well w/ spacing to every other week. https://t.co/ywvsDMxS6M

Links:

Dr. John Cush RheumNow ( View Tweet)

Logical + Data-driven = Annoying. (If you have high standards does that make you arrogant?)

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! When you're hot you're hot! Watch it on youtube>> https://t.co/GlqMzjUnhE or listen to the podcast on iTues, Apple podcast or on Stitcher or SoundCloud>> https://t.co/a1zE7VXtog

Links:

Dr. John Cush RheumNow ( View Tweet)

China retrospective study of 727 SoA abd 857 RA pts shows risk of H. Zoster same between SpA & RA (aHZ=0.97), but was significantly higher with MTX (adj HR 3.47) and infliximab (adj HR 10.67) https://t.co/gpictKPpIT

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! When youre hot youre hot! Watch it on youtube>> https://t.co/GlqMzjUnhE or listen to the podcast in your car on iTues, Apple podcast or on Stitcher or SoundCloud>> https://t.co/a1zE7VXtog

Links:

Dr. John Cush RheumNow ( View Tweet)

How would you describe your "BEST" patient in just 3 words? https://t.co/j1CEAiUdvo

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×